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Background: The genetic background, transmissibility and virulence of MRSA have been poorly investigated in the cystic fibrosis (CF) population.
The aim of this multicentre study was to analyse MRSA strains isolated from CF patients attending nine Italian CF care centres during a two-year
period (2004–2005). All CF patients infected by MRSA were included.
Method: Antibiotic susceptibility testing, SCCmec typing, Panton–Valentine Leukocidin (PVL) production, and Multi Locus Sequence Typing
(MLST) analysis were carried out on collected isolates (one strain per patient).
Results: One hundred and seventy-eight strains isolated from 2360 patients attending the participating centres were analysed.We detected 56 (31.4%)
SCCmec IV PVL-negative strains, with a resistance rate of 80.3% to clindamycin and of 14.5% to trimethoprim/sulphamethoxazole. MLST analysis
showed that many isolates belonged to known epidemic lineages. The largest clone grouping of 29 isolates from 6 centres had the genetic background
(ST8-MRSA-IV) of the American lineages USA300 and USA500, thus demonstrating the diffusion of these strains in a population considered at risk
for hospital associated infections.
Conclusions: Known MRSA epidemic clones such as USA600, USA800, USA1100, and UK EMRSA-3 were described for the first time in Italy.
The diffusion ofMRSA strains with high pathogenic potential in the CF population suggests that analysis of theMRSA strains involved in pulmonary
infections of these patients is needed.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: MRSA; SCCmec; MLST; Cystic fibrosis1. Introduction
Cystic fibrosis (CF) patients' lungs are the ideal habitat for
several bacterial species and Staphylococcus aureus is usually
the first pathogen detected in the respiratory tract. In the pre-
antibiotic era, this pathogen was the major cause of morbidity⁎ Corresponding author at: Cystic Fibrosis Centre, Azienda Ospedaliero-
Universitaria Anna Meyer, Viale Pieraccini 24, 50139, Florence, Italy. Tel.: +39
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doi:10.1016/j.jcf.2011.06.005and mortality. Recently a further cause for concern has been
the emergence of meticillin-resistant Staphylococcus aureus
(MRSA) [1].
Data from the American CF Foundation Patient Registry
shows that the prevalence of MRSA infection in CF has
increased from 6.1% in 2001 to 23.7% in 2009 [1].
Although the contribution of MRSA infection to lung damage
in CF patients is incompletely understood, some studies indicate
that the presence of MRSA in CF patients' airways may worsen
their clinical condition [2]. It has also been recently reported in a
large CF population that persistent MRSA infection affects lungd by Elsevier B.V. All rights reserved.
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Society of Cystic Fibrosis Society suggest attempting to eradicate
MRSA, therapeutic strategies still vary among CF centres [5].
MRSA was first recognised as being acquired from hospita-
lised patients (HA-MRSA), but the onset of MRSA infection
outside the hospital setting, due to community-acquired strains
(CA-MRSA), has recently been described with increasing
frequency [6]. Although HA-MRSA strains are known to be
responsible for infections in hospitalised patients, highly virulent
CA-MRSA strains are increasing worldwide and are implicated
in serious infections, including necrotising pneumonia and severe
sepsis, as well as fatal outbreaks [7]. Recently CA-MRSA strains
have been found in hospitals, displacing classic hospital-
associated strains, consistent with the hypothesis that the former
may be more virulent [8].
CA-MRSA and HA-MRSA can be distinguished on the basis
of a mobile genetic element called the staphylococcal cassette
chromosome mec (SCCmec) integrated into the MRSA chro-
mosome. Currently, eight SCCmec types are recognisable: I, II,
III, IV, V, VI, VII and VIII [9–12].
HA-MRSA are characterised by SCCmec types I, II, III
and VIII while SCCmec types IV, V, VI and VII are mainly
associated with CA-MRSA isolates. In SCCmec type I, no
antibiotic resistance determinants except for those carried by
mecA (beta-lactams) are found. In contrast, types II and III
contain multiple determinants for non-beta-lactam antibiotic
resistance and provide a molecular explanation for the multiple
drug resistance often documented in MRSA isolates circulating
in healthcare environments.
CA-MRSA strains are more virulent than HA-MRSA strains
due to the production of many virulent factors such as Panton–
Valentine Leukocidin (PVL), which can be associated with
necrotising pneumonia [13].
To date, few studies have investigated the genetic back-
ground, transmissibility, antibiotic susceptibility and virulence
of MRSA strains in the CF population [14–19].
The prevalence of CA-MRSA is increasing in CF patients
with newly acquired strains being mostly represented by CA-
MRSA indicating that CA-MRSA strains are now circulating in
the CF population and are responsible for new colonisations
[20,21].
The goal of this study was to investigate the epidemiology
and genetic background of MRSA infecting the CF population.
This knowledge could help identify MRSA with different
pathogenicities and consequently improve prevention and treat-
ment strategies.
2. Materials and methods
2.1. Patients
A two-year (2004–2005) multicentre study on MRSA in-
volved 2362 CF patients attending 9 (40.9%) out of 22 Italian
Cystic Fibrosis (CF) centres. All CF patients infected by MRSA
in the studied period were included. No CF patients were shared
among different CF centres. Patients were considered infected
in the case of one positive culture. One MRSA strain isolatedfrom respiratory samples of each of the MRSA infected patient
was collected and then stored at −80 °C.
2.2. Bacterial strains
All collected bacterial isolates were identified as Staphylo-
coccus aureus by typical colony morphology on selective culture
media (Mannitol Salt 2 Agar, Biomerieux) and positive results
of the Slidex Staph Plus (Biomerieux). MRSA isolates were
identified using Oxa Screen Test Agar (Becton and Dickinson)
and MRSA ID (Biomerieux).
2.3. Characterisation of SCCmec types
SCCmec typing of collected isolates was performed as
previously described [9,22,23]. MRSA isolates were tested for
the presence of the genes (lukS-lukF) encoding a subunit of
PVL, following the protocol of Lina and colleagues [24].
2.4. Evaluation of antimicrobial susceptibility
Antibiotic susceptibility was evaluated by assessing the
activity of a large panel of drugs. The antibiotic susceptibility
profile of MRSA strains collected was evaluated by disc dif-
fusion test on Mueller–Hinton agar. Susceptibility to glyco-
peptides was evaluated by Etest macromethod as previously
described [25].
For isolates that tested resistant to erythromycin but sus-
ceptible to clindamycin by single-agent testing, a D-zone test to
detect inducible clindamycin resistance was performed.
All assays were performed according to the Clinical
Laboratory Standards Institute Guidelines [26].
Susceptibility patterns of MRSA isolates with different
characteristics were compared. Proportions were analysed using
chi-square and Fisher's exact test to assess for significance
(pb0.05).
2.5. Multilocus sequence typing (MLST) analysis
MLST was performed on MRSA isolates for epidemiolog-
ical purposes as previously described [27].
3. Results
One hundred and seventy-eight (7.5%) putative MRSA
strains were collected from as many patients out of 2362 CF
patients attending CF centres in Italy in the period (2004–2005).
All bacterial isolates were then identified as MRSA.
3.1. Identification of SCCmec type
The SCCmec type of 153 of 178 (85.9%) MRSA strains was
identified. We recognised 88 (49.5%) strains with SCCmecI,
56 (31.4%) strains with SCCmecIV, 2 (1.2%) with SCCmecII
and 7 (3.9%) with SCCmecIII. Twelve strains (6.7%) showed
a multiple SCCmec profile and 13 (7.3%) strains had an
undetermined SCCmec type.
Table 2
MLST analysis of MRSA strains.
Sequence type SCCmec type No. of strains (centres) Clone
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lukS-lukF encoding for PVL, but no positive strains were found.
HA-MRSA strains were mainly SCCmec type I.5 I 26 (a,b,c,f,g,h) UK/EMRSA-3
5 II 1 (h) USA100
5 IV 9 (a,h) Pediatric/USA800
8 IV 29 (a,b,d,e,f,h) USA500 and USA300
30 IV 2 (h) Southwest Pacific
45 IV 1 (c) Berlin/USA600
228 I 20 (a,b,c,e,g,h) Southern Germany
239 III 1 (g) Brazilian/Hungarian
247 I 9 (a,b,c,f,g,h,i) Iberic
Total 983.2. Antimicrobial susceptibility testing
The resistance rates of the SCCmecI and SCCmecIV strains
are compared in Table 1. No resistance against glycopeptides
(vancomycin and teicoplanin) and oxazolidinones (linezolid)
was found, the most active antibiotics among the other classes
were tetracyclines (minocycline and doxycycline with 4.4%
and 13.4% of resistant strains respectively), trimethoprim/
sulfamethoxazole (13.2%), and rifampin (33%). SCCmecI
demonstrated a higher resistance rate profile in comparison
to SCCmecIV strains for gentamicin and doxycycline. The
difference in gentamicin resistance between the two groups was
statistically significant (pb0.05).3.3. MLST analysis
MLST analysis showed that 98 isolates belonged to known
epidemic lineages (Table 2). The largest clone was ST8-MRSA-
IV which accounted for 29 strains collected from 6 different
centres. The second most represented epidemic clone (26 strains
from 6 CF centres) was UK/EMRSA-3 (ST5-MRSA-I),
followed by the Southern Germany clone (ST228-MRSA-I)
grouping 20 isolates from 6 centres, the Pediatric/USA800 (ST5-
MRSA-IV) I and the Iberian clone (ST247-MRSA-I), both
grouping 9 strains isolated from 2 to 7 CF centres respectively.
Other important MRSA lineages such as USA100 (ST5-
MRSA-II), the Brazilian/Hungarian clone (ST239-MRSAIII),
the Southwest Pacific, Berlin/USA600 clone (ST30-MRSA-IV
and ST45-MRSA-IV respectively) were represented by few
isolates (1 to 2 strains).Table 1
Characteristics and antibiotic resistance profiles of MRSA strains.
Antimicrobial
agent
Prevalence of resistant strains n (%)
MRSA (total)
(n=138)
SCCmecI
(n=82)
SCCmecIV
(n=56)
p
Tobramycin 86.9 83.6 90.7 NS
Gentamicin 75.3 83.7 62.9 b0.05
Ciprofloxacin 75 74 78.1 NS
Levofloxacin 55.5 58.7 50.9 NS
Rifampin 33 30.8 36.3 NS
Minocycline 4.4 5.1 3.5 NS
Doxycycline 13.4 17.9 7.1 NS
Erythromycin 90.5 95 83.9 NS
Clindamycin a 80.4 82.5 80.3 NS
Trimeth./sulfam 13.2 12.3 14.5 NS
Linezolid 0 0 0 –
Vancomycin 0 0 0 –
Teicoplanin 0 0 0 –
a Includes inducible resistance.4. Discussion
Few studies have been published about the genetic back-
ground of MRSA in CF patients. The increasing prevalence
of CA-MRSA in the CF population has been demonstrated, as
well as the fact that they are primarily responsible for new
colonisations in these patients. PVL-positive CA-MRSA strains
have already been isolated from CF patients and their diffusion
demonstrated [20,28].
In this study a high prevalence (31.4%) of SCCmecIV,
commonly associated with CA-MRSA was found [14]. All
these SCCmecIV isolates were negative for PVL genes, fre-
quently described in CA-MRSA.
In contrast with other reports [20], only 1.1% of the HA-
MRSA isolates harboured SCCmec II while the most repre-
sented was SCCmecI (49.4%). This latter evidence concords
with a recent paper demonstrating a high prevalence of ST228-
MRSA-I clone in CF patients [15].
Regarding antibiotic susceptibility patterns, previous findings
have demonstrated that most CA-MRSA isolates are more sus-
ceptible than HA-MRSA to tetracycline–minocycline, clindamy-
cin, gentamicin, rifampicin and trimethoprim/sulfamethoxazole
[29]. SCCmec type IV strainsweremore susceptible than SCCmecI
to gentamicin and doxycycline, with the difference in gentamicin
resistance rates between the two groups being statistically sig-
nificant (pb0.05).
Clindamycin resistance was high both for SCCmecIV and
SCCmecI strains (80.3% and 82.5% respectively). Most CA-
MRSA are associated with good susceptibility to clindamycin
[30], but high clindamycin resistance has been demonstrated in
CA-MRSA isolated from different countries in outpatients and
nosocomial settings including patients with CF [31,32]. Unlike
other studies a good susceptibility rate to clindamycin is not
associated with SCCmecIV [33].
We found that the epidemiological picture of MRSA in
our study was different from the situation in the United States
where only a few lineages predominate such as USA500 and
PVL-positive USA300 [34]. The frequency of isolation of
USA300 has recently increased worldwide, being reported in
Germany, Belgium, Denmark, the Netherlands, the UK, France,
Austria, Spain and Japan [35–37]. So far few reports describe
isolated infections by USA300 in nosocomial and outpatient
settings in Italy [38,39].
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analysis in this study showed that most of the SCCmecIV
isolates (73%) belonged to known epidemic lineages with
global diffusion.
The most represented clone identified by MLST analysis was
ST8-MRSA-IV, grouping 29 isolates in 6 different Italian CF
centres. This is the genetic background characteristic of the
American lineages USA500 and USA300 [40]. The other most
commonly found clone, characterised by SCCmecIV, among
the Italian isolates was the Pediatrics/USA800 with 9 strains
isolated from two centres.
The HA-MRSA isolates represented the majority of MRSA
strains isolated from our study (54.4%). Fifty-seven (58.7%)
out of 97 HA-MRSA strains belonged to epidemic lineages, the
most frequent being ST5-MRSA-I described in the UK with
26 isolates collected from 6 different centres, followed by the
Southern Germany (ST228-MRSA-I) clone with 20 strains from
6 centres. The Iberian clone, an HA-MRSA lineage frequently
associated with hospital outbreaks in European Countries [40],
was represented by 9 strains isolated from 7 centres.
The epidemiological picture of MRSA emerging from this
national overview showed that 98 (55%) out of 178 isolates
belonged to important epidemic lineages involved in serious
outbreaks worldwide. This was the first description in Europe
of a large spread of MRSA strains with the genetic background
of important American epidemic clones. This was also the first
description in Italy of the following worldwide diffused epidemic
strains: Berlin (USA600), Pediatric (USA800), Southwest Pacific
(USA1100), and UK EMRSA-3 [40]. One limitation of this
study was that analyses were performed on strains isolated in
2004 and 2005, therefore this first overview epidemiology on
MRSA patients in Italy needs to be updated by studying strains of
more recent isolates [41].
The high prevalence of MRSA isolates representing epidemic
clones, characterised by severe virulence and transmissibility,
suggests that the epidemiology ofMRSA is changing rapidly. The
diffusion in the CF population ofMRSA strains characterised by a
high pathogenic potential could have a severe impact on the
clinical status of CF patients, and therefore careful surveillance
and close monitoring of MRSA infections is essential.Conflict of interest
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